Munshi, Nikhil C.

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., et al. (2015) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 309

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Maura, F., Bolli, N., Angelopoulos, N., Dawson, K. J., Leongamornlert, D., Martincorena, I., Mitchell, T. J., Fullam, A., Gonzalez, S., Szalat, R., et al. (2019) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 278

Genomic patterns of progression in smoldering multiple myeloma

Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 222

RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 219

Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gullà, A., Rossi, M., Neri, A., Giordano, A., Munshi, N. C., et al. (2013) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 219

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 212

Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression

Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 187

A practical guide for mutational signature analysis in hematological malignancies

Maura, F., Degasperi, A., Nadeu, F., Leongamornlert, D., Davies, H., Moore, L., Royo, R., Ziccheddu, B., Puente, X. S., Avet-Loiseau, H., et al. (2019) · Nature Communications

Cancer Genomics and DiagnosticsAcute Myeloid Leukemia Research

Cited by 184

Timing the Initiation of Multiple Myeloma

Rustad, E. H., Yellapantula, V., Leongamornlert, D., Bolli, N., Ledergor, G., Nadeu, F., Angelopoulos, N., Dawson, K. J., Mitchell, T. J., Osborne, R. J., et al. (2020) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 165

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

Hideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2003) · Oncogene

Multiple Myeloma Research and TreatmentsCytokine Signaling Pathways and Interactions

Cited by 164

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 162

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia

Histone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments

Cited by 159

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

Lin, Y., Martin, T. G., Usmani, S. Z., Berdeja, J. G., Jakubowiak, A. J., Agha, M. E., Cohen, A. D., Deol, A., Htut, M., Lesokhin, A. M., et al. (2023) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 120

RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 109

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

Gullà, A., Hideshima, T., Bianchi, G., Fulciniti, M., Kemal Samur, M., Qi, J., Tai, Y.-T., Harada, T., Morelli, E., Amodio, N., et al. (2018) · Leukemia

Cancer-related gene regulationMultiple Myeloma Research and Treatments

Cited by 102

Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal Antibody) in patients with multicentric castleman disease

Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., et al. (2015) · Clinical Cancer Research

Viral-associated cancers and disordersAutoimmune and Inflammatory Disorders Research

Cited by 97

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

Ghobrial, I. M., Weller, E., Vij, R., Munshi, N. C., Banwait, R., Bagshaw, M., Schlossman, R., Leduc, R., Chuma, S., Kunsman, J., et al. (2011) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 95

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan-Khan, A., Ruehle, M., Rharbaoui, F., et al. (2019) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 85

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

Mateos, M., Orlowski, R. Z., Ocio, E. M., Rodríguez‐Otero, P., Reece, D., Moreau, P., Munshi, N., Avigan, D. E., Siegel, D. S., Ghori, R., et al. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 73

Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group

Samur, M. K., Aktas Samur, A., Fulciniti, M., Szalat, R., Han, T., Shammas, M., Richardson, P., Magrangeas, F., Minvielle, S., Corre, J., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 70

Antigen-mediated regulation in monoclonal gammopathies and myeloma

Nair, S., Sng, J., Boddupalli, C. S., Seckinger, A., Chesi, M., Fulciniti, M., Zhang, L., Rauniyar, N., Lopez, M., Neparidze, N., et al. (2018) · JCI Insight

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 60

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kelly, K. R., Ailawadhi, S., Siegel, D. S., Heffner, L. T., Somlo, G., Jagannath, S., Zimmerman, T. M., Munshi, N. C., Madan, S., Chanan-Khan, A., et al. (2021) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 46

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Jagannath, S., Chanan-Khan, A., Heffner, L. T., Avigan, D., Zimmerman, T. M., Lonial, S., Lutz, R. J., Engling, A., Uherek, C., Osterroth, F., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 44

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 43